A world-first clinical trial led by the Centre for Eye Research Australia shows vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma patients. Chief Optometric Editor, Ben Casella, OD, FAAO, says it's exciting news, but more research needs to be done.
Related: Glaucoma & ocular surface preservation: Key factors for ODs to consider
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.